Abstract
ChAdOx1 nCoV-19 vaccination has been associated with the rare side effect; vaccine-induced immune thrombotic thrombocytopenia (VITT). The mechanism of thrombosis in VITT is associated with high levels of neutrophil extracellular traps (NETs). The present study examines whether key markers for NETosis, such as H3-NETs and calprotectin, as well as syndecan-1 for endotheliopathy, can be used as prognostic factors to predict the severity of complications associated with ChAdOx1 vaccination. Five patients with VITT, 10 with prolonged symptoms and cutaneous hemorrhages but without VITT, and 15 with only brief and mild symptoms after the vaccination were examined. Levels of H3-NETs and calprotectin in the vaccinated individuals were markedly increased in VITT patients compared to vaccinees with milder vaccination-associated symptoms, and a strong correlation (r ≥ 0.745, p < 0.001) was found with severity of vaccination side effects. Syndecan-1 levels were also positively correlated (r = 0.590, p < 0.001) in vaccinees to side effects after ChAdOx1 nCoV-19 vaccination. We hypothesize that the inflammatory markers NETs and calprotectin may be used as confirmatory tests in diagnosing VITT.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference29 articles.
1. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis
2. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
3. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
4. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
5. Renaming of AZ Vaccine: Vaxzevria (Previously COVID-19 Vaccine AstraZeneca): Link between the Vaccine and the Occurrence of Thrombosis in Combination with Thrombocytopenia. European Medicines Agency (europa.eu)
https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-COVID-19-vaccine-astrazeneca-link-between-vaccine-occurrence-thrombosis
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献